Decades of research has yielded in the development of dozens of disease modifying therapies. Albeit effective in reducing relapse rates and MRI lesions, these therapies do not reverse existing lesions nor halt ongoing neurodegeneration. Previous preclinical studies have revealed that neuronal activity can influence remyelination and that different patterns of neuronal activity can be sensed by oligodendroglial cells. These techniques, however, are not translatable to people with MS due to their invasive nature. In that regard, we investigate the potential of non-invasive neuromodulation through tACS in the cuprizone model of MS.